Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. provides long-term care pharmacy services for residents of long-term health care facilities. The company partners with LTCFs through a locally based pharmacy model to dispense medications and deliver technology-enabled clinical and administration services intended to support drug-regimen adherence and reduce medication-administration errors.
Recurring GRDN news covers quarterly results and guidance, resident and prescription-volume trends, the effects of drug-pricing changes, healthcare conference presentations, and capital-structure activity involving Class A common stock. Company updates also reference its pharmacy network, facility relationships, and service categories across assisted living, behavioral health, group home, and other long-term care settings.
Guardian Pharmacy Services (NYSE: GRDN) reported Q1 2026 results: revenue $336.6M (+2% YoY), net income $13.5M, adjusted EBITDA $29.8M, and diluted EPS $0.21. Cash was $64.9M with no long-term debt under the credit facility. Residents served rose to ~207,000 (+10% YoY). Updated FY2026 guidance: revenue $1.40B–$1.42B, adjusted EBITDA $123M–$127M. Company completed a non-dilutive secondary offering increasing public float and filed a new shelf registration; no proceeds retained and no change to outstanding Class A shares.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Bank of America 2026 Healthcare Conference in Las Vegas on Wednesday, May 13, 2026. Fred Burke, President and CEO, will take part in a 9:20 a.m. PDT fireside chat. A live audio webcast will be available via the company's investor website.
Guardian Pharmacy Services (NYSE: GRDN) will release first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Management will host a conference call at 4:30 p.m. ET to discuss results.
The call will stream via audio webcast at the company's investor site and is reachable by U.S./Canada dial-in +1 (833) 461-5787, international +1 (585) 542-9983, conference ID 621845633. A replay will be available shortly after the call.
Guardian Pharmacy Services (NYSE: GRDN) priced an upsized underwritten public offering of 6,000,000 Class A shares at $31.00 per share, expected to close on March 20, 2026. 4,980,000 shares are being sold by selling stockholders and 1,020,000 shares are a synthetic secondary to be repurchased by Guardian.
Underwriters have a 30‑day option for up to an additional 900,000 shares. Guardian will not retain net proceeds from selling stockholders and expects the repurchases to complete by March 24, 2026.
Guardian Pharmacy Services (NYSE: GRDN) launched a proposed underwritten public offering of 5,000,000 Class A shares on March 18, 2026, including 3,980,000 shares by selling stockholders and 1,020,000 newly issued shares by Guardian.
The underwriters have a 30-day option for up to an additional 750,000 shares. Guardian intends a non-dilutive "Synthetic Secondary": net proceeds it receives will be used to repurchase an equal number of Class A shares, keeping total outstanding Class A shares unchanged. A shelf registration on Form S-3 became effective November 3, 2025.
Guardian Pharmacy Services (NYSE: GRDN) reported Q4 2025 revenue of $397.6M (+17% YoY; organic +12%) and Q4 Adjusted EBITDA of $39.5M (+53% YoY). Full-year 2025 revenue was $1.45B (+18%); Adjusted EBITDA $115.1M (+27%); net income $49.0M versus a ($71.0M) loss in 2024. Cash totaled $65.6M at year-end. The company raised 2026 Adjusted EBITDA guidance to $120M–$124M while maintaining the prior 2026 revenue outlook of $1.40B–$1.42B. Operational highlights included one acquisition, improved vaccine profitability, and ~205,000 residents served at year-end.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
CEO Fred Burke and CFO David Morris will take part in a fireside chat on Monday, March 16, 2026 at 10:40 a.m. ET. A live audio webcast and a replay available for 90 days will be hosted on the company investor site.
Guardian Pharmacy Services (NYSE: GRDN) will present at the Raymond James Institutional Investors Conference in Orlando on Monday, March 2, 2026 at 1:40 p.m. ET. A live audio webcast will be available via the company's investor site, with a replay accessible shortly after the event for 90 days.
Guardian Pharmacy Services (NYSE: GRDN) will release fourth quarter and full‑year 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss results.
The call is available via audio webcast at the company's investor site and by dialing the provided U.S. and international numbers; a replay will be available shortly after the call and remain online for approximately 60 days.
Guardian Pharmacy Services (NYSE: GRDN) reiterated its 2025 guidance and issued initial 2026 outlook ahead of its J.P. Morgan Healthcare Conference presentation on January 14, 2026. The company reaffirmed 2025 revenue guidance of $1.43B–$1.45B and adjusted EBITDA of $104M–$106M. For 2026 Guardian expects revenue of $1.40B–$1.42B after Inflation Reduction Act drug price reductions and WAC cuts, and adjusted EBITDA of $115M–$118M (~11% growth vs. 2025 guidance) with adjusted EBITDA margin above 8%. The company also completed a single-location pharmacy acquisition in Montana to add a new territory.